Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Advertising and promotion teleconference

This article was originally published in The Gray Sheet

Executive Summary

Advertising and promotion teleconference: FDA and the Food and Drug Law Institute are co-sponsoring a teleconference slated for May 4 on FDA regulation of device, drug and biologics promotional activity. Specific issues to be discussed include: FDA's draft policy on continuing medical education; direct-to-consumer promotion; and the effect of marketing and advertising issues on efforts to better educate health professionals and facilitate public health. Speakers will include Byron Tart, director of the FDA device center's promotion and advertising policy staff, and William Purvis, director of the advertising and promotional labeling staff at the agency's Center for Biologics Evaluation and Research. For more information, contact FDLI at 202/371-1420...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT003514

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel